HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.

AbstractOBJECTIVES:
Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing severe, treatment emergent, cumulative OXA-induced peripheral neuropathy (OXAIPN).
METHODS:
200 colorectal cancer patients, scheduled to receive OXA-based chemotherapy, were prospectively followed. Detailed neurological assessment employing the clinical Total Neuropathy Score (TNSc), oncological rating scales (National Common Institute-Common Toxicity Criteria V.3) and nerve conduction studies (NCS) were performed at baseline, mid-treatment and at the end of chemotherapy. Symptoms of OXA-induced acute neurotoxicity were systematically recorded.
RESULTS:
According to TNSc, 36 (18%) patients developed grade 3 OXAIPN. These patients were predominantly men (p=0.005), presented a significant decrease in all NCS (p<0.001), reported more acute neuropathic symptoms (p<0.001) and received higher OXA cumulative dose (p=0.003). Multivariate analysis showed that three variables obtained at intermediate follow-up, namely, the number of acute symptoms (OR 1.9; CI 95% 1.2 to 3.2; p=0.012) and the >30% decrease in sensory nerve action potential amplitude from the baseline value in radial (OR 41.4; CI 95% 4.98 to 343.1; p=0.001) and dorsal sural nerves (OR 24.96; CI 95% 2.6 to 239.4; p=0.005) were independently associated with the risk of developing severe OXAIPN.
CONCLUSIONS:
High-grade OXA neurotoxicity can be predicted by clinical and neurophysiological information obtained at mid-treatment. Neurological assessment of acute neuropathy symptoms and radial and dorsal sural nerves NCS should be carefully monitored to predict and hopefully prevent the induction of severe OXAIPN.
AuthorsRoser Velasco, Jordi Bruna, Chiara Briani, Andreas A Argyriou, Guido Cavaletti, Paola Alberti, Barbara Frigeni, Mario Cacciavillani, Sara Lonardi, Diego Cortinovis, Marina Cazzaniga, Cristina Santos, Haralabos P Kalofonos
JournalJournal of neurology, neurosurgery, and psychiatry (J Neurol Neurosurg Psychiatry) Vol. 85 Issue 4 Pg. 392-8 (Apr 2014) ISSN: 1468-330X [Electronic] England
PMID23813745 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Pharmacological
  • Organoplatinum Compounds
  • Oxaliplatin
Topics
  • Aged
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Biomarkers, Pharmacological
  • Colorectal Neoplasms (complications, drug therapy)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neural Conduction (drug effects, physiology)
  • Organoplatinum Compounds (adverse effects, therapeutic use)
  • Oxaliplatin
  • Peripheral Nervous System Diseases (chemically induced, complications, diagnosis)
  • Predictive Value of Tests
  • Prospective Studies
  • Sural Nerve (drug effects, physiology)
  • Symptom Assessment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: